
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
HMG-1/HMGB1 CRISPR Activation Plasmid (m) | sc-420871-ACT | 20 µg | $397.00 | |||
HMG-1/HMGB1 CRISPR Activation Plasmid (m2) | sc-420871-ACT-2 | 20 µg | $397.00 |
Hmgb1 encodes HMG-1/HMGB1, an abundant non-histone chromatin protein that binds and bends DNA to regulate nucleosome dynamics, transcription, replication, and DNA repair. In the nucleus, HMGB1 supports genome stability through participation in DNA damage responses and influences gene expression programs linked to cell fate decisions. When released extracellularly, HMGB1 functions as a damage-associated molecular pattern that modulates innate immune signaling and inflammatory pathways, including receptor-mediated responses involving TLRs and RAGE. Dysregulated HMGB1 activity is widely studied in contexts such as sterile inflammation, autoimmunity, neuroinflammation, sepsis biology models, and tumor-associated inflammation in mouse systems.
HMG-1/HMGB1 CRISPR Activation Plasmid (m) provides a targeted, non-destructive approach to upregulating endogenous Hmgb1 expression without altering the underlying DNA sequence.
HMG-1/HMGB1 CRISPR Activation Plasmid (m) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the Hmgb1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the Hmgb1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous HMG-1/HMGB1 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native Hmgb1 locus and enabling the study of HMG-1/HMGB1-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of HMG-1/HMGB1 pathway restoration in tumor cells with silenced or reduced Hmgb1 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.